by QMB Innovation Centre | Aug 7, 2019 | News
hVIVO successfully completes RSV challenge study in Older Adults London, UK – 6 August 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral challenge, announces the successful...
by QMB Innovation Centre | Feb 13, 2019 | News
Location: Queen Mary Innovation Centre, 5 Walden Street, London, E1 2EF Date: 13th February Time: 14.00 – 19.30 The track record of success delivered by London’s academic institutions, their commercial teams and the spin out companies they have collectively created is...
by QMB Innovation Centre | Oct 8, 2018 | News
hVIVO has signed new contracts with a leading global biopharmaceutical company ▪ Contracted for two respiratory syncytial virus (RSV) human challenge studies ▪ Studies projected to deliver a total of c.£9m in revenue from Q4’18 through to end of 2019 ▪ Builds...
by QMB Innovation Centre | Sep 20, 2018 | News
Queen Mary joins London cancer research powerhouse The city of London will be transformed into a world leading hub for cancer biotherapeutics research and treatment, with a new £14 million investment from Cancer Research UK, announced today. The new Cancer...
by QMB Innovation Centre | Sep 5, 2016 | News
hVIVO plc (AIM: HVO), the pioneer of human disease models, is delighted to announce that the Company’s landmark asthma stratification initiative is now underway, with the first volunteer inoculated with human rhinovirus (HRV) at hVIVO’s London based clinical research...
by QMB Innovation Centre | Sep 5, 2016 | News
Immuno-Oncology Investment Forum Immuno-Oncology (IO) has been one of, if not the, hottest area in biopharma over recent years. High profile financings, approvals and challenges have emerged and competition for new innovative programmes is fierce. To complement the...
